Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study
Journal of Alzheimer's Disease · 21.03.2023 · 92 (2) · 653-665
DOI: 10.3233/jad-221238 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 21.03.2023. Verfasst von Mikkel Pejstrup Agger und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Zealand University Hospital, Denmark. Hauptthemen laut MEDLINE: Alzheimer Disease, Phototherapy. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Recent studies suggested induction of 40 Hz neural activity as a potential treatment for Alzheimer’s disease (AD). However, prolonged exposure to flickering light raises adherence and safety concerns, encouraging investigation of tolerable light stimulation protocols.
Objective
To investigate the safety, feasibility, and exploratory measures of efficacy.
Methods
This two-stage randomized placebo-controlled double-blinded clinical trial, recruited first cognitive healthy participants (n = 3/2 active/placebo), and subsequently patients with mild-to-moderate AD (n = 5/6, active/placebo). Participants were randomized 1:1 to receive either active intervention with 40 Hz Invisible Spectral Flicker (ISF) or placebo intervention with color and intensity matched non-flickering white light.
Results
Few and mild adverse events were observed. Adherence was above 86.1% of intended treatment days, with participants remaining in front of the device for >51.3 min (60 max) and directed gaze >34.9 min. Secondary outcomes of cognition indicate a tendency towards improvement in the active group compared to placebo (mean: –2.6/1.5, SD: 6.58/6.53, active/placebo) at week 6. Changes in hippocampal and ventricular volume also showed no tendency of improvement in the active group at week 6 compared to placebo. At week 12, a potential delayed effect of the intervention was seen on the volume of the hippocampus in the active group compared to placebo (mean: 0.34/–2.03, SD: 3.26/1.18, active/placebo), and the ventricular volume active group (mean: –0.36/2.50, SD: 1.89/2.05, active/placebo), compared to placebo.
Conclusion
Treatment with 40 Hz ISF offers no significant safety or adherence concerns. Potential impact on secondary outcomes must be tested in larger scale clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Zealand University Hospital, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Denmark.
- Department of Radiology Zealand University Hospital, Denmark.
- Department of Photonics Engineering, Technical University of Denmark, Denmark.
- OptoCeutics ApS, Kgs. Lyngby, Denmark.
- Department of Applied Mathematics and Computer Science, Technical University of Denmark, Denmark.
Zitieren
APA
Agger, M. P., Danielsen, E. R., Carstensen, M. S., Nguyen, N. M., Horning, M., Henney, M. A., Jensen, C. B. R., Baandrup, A. O., Kjær, T. W., Madsen, K. H., Miskowiak, K., Petersen, P. M., & Høgh, P. (2023). Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study. Journal of Alzheimer's Disease, 92(2), 653-665. https://doi.org/10.3233/jad-221238
Vancouver
Agger MP, Danielsen ER, Carstensen MS, Nguyen NM, Horning M, Henney MA, et al. Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study. Journal of Alzheimer's Disease. 2023;92(2):653-665. doi:10.3233/jad-221238
BibTeX
@article{Agger2023,
author = {Agger, Mikkel Pejstrup and Danielsen, Else Rubæk and Carstensen, Marcus Schultz and Nguyen, N Mai and Horning, Maibritt and Henney, Mark Alexander and Jensen, Christopher Boe Ravn and Baandrup, Anders Ohlhues and Kjær, Troels Wesenberg and Madsen, Kristoffer Hougaard and Miskowiak, Kamilla and Petersen, Paul Michael and Høgh, Peter},
title = {Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer’s Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study},
journal = {Journal of Alzheimer's Disease},
year = {2023},
volume = {92},
number = {2},
pages = {653--665},
doi = {10.3233/jad-221238}
}
EUVIMED